CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease
Authors
Keywords
-
Journal
BLOOD
Volume 120, Issue 7, Pages 1449-1457
Publisher
American Society of Hematology
Online
2012-05-24
DOI
10.1182/blood-2011-10-384784
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial
- (2012) Paul P Tak et al. ANNALS OF THE RHEUMATIC DISEASES
- Pharmacokinetic and Pharmacodynamic Evaluation of the Novel CCR1 Antagonist CCX354 in Healthy Human Subjects: Implications for Selection of Clinical Dose
- (2011) D J Dairaghi et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease
- (2011) Evangelos Terpos et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?
- (2011) Gareth J. Morgan CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- CCR1 as a target for multiple myeloma
- (2011) Sonia Vallet et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Therapeutic potential of CCR1 antagonists for multiple myeloma
- (2011) Angela R Karash et al. Future Medicinal Chemistry
- A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
- (2011) S Vallet et al. LEUKEMIA
- Advances in the understanding of myeloma bone disease and tumour growth
- (2010) Shmuel Yaccoby BRITISH JOURNAL OF HAEMATOLOGY
- Interleukin-6 in bone metastasis and cancer progression
- (2010) Tasnim Ara et al. EUROPEAN JOURNAL OF CANCER
- The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients
- (2010) Yanran Cao et al. EXPERIMENTAL HEMATOLOGY
- Deficiency of Chemokine Receptor CCR1 Causes Osteopenia Due to Impaired Functions of Osteoclasts and Osteoblasts
- (2010) Akiyoshi Hoshino et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease
- (2010) M. J. Walters et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases
- (2009) Evangelos Terpos et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Chemokine receptor antagonists: Part 1
- (2009) James E Pease et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma
- (2009) M Roussou et al. LEUKEMIA
- Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment
- (2009) O. Sezer ONCOLOGIST
- Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma
- (2008) O. Murillo et al. CLINICAL CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started